Shilpa Medicare spurts as USFDA accepts corrective action plan

Shilpa Medicare rose 5.22% to Rs 718.10 at 12:07 IST on BSE after the US drug regulator accepted company's corrective and preventive action plan in response to the form 483 issued at the end of Raichur plant inspection.

The announcement was made during market hours today, 12 April 2017.

Meanwhile, the S&P BSE Sensex was down 138.09 points, or 0.46% to 29,650.26.

On the BSE, 84,000 shares were traded in the counter so far, compared with average daily volumes of 7,110 shares in the past one quarter. The stock had hit a high of Rs 748.95 and a low of Rs 688.40 so far during the day.

The stock hit a record high of Rs 786.75 on 21 December 2016. The stock hit a 52-week low of Rs 434.50 on 12 April 2016.

The stock had outperformed the market over the past one month till 11 April 2017, rising 6.41% compared with 2.91% rise in the Sensex. The scrip had, however, underperformed the market in past one quarter, falling 3% as against Sensex's 9.76% rise.

The mid-cap company has equity capital of Rs 8.01 crore. Face value per share is Re 1.

Shilpa Medicare announced that the US Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) for the company's Active Pharmaceutical Ingredient (API) manufacturing facilities located at Raichur, Karnataka which was inspected between 12th and 16th December 2016. The inspection has now been closed by the USFDA. The company had submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines in response to the form 483 issued at the end of inspection. The USFDA has reviewed the CAPA and has found them acceptable.

On a consolidated basis, Shilpa Medicare's net profit dropped 37.05% to Rs 17.45 crore on 8.23% growth in net sales to Rs 183.58 crore in Q3 December 2016 over Q3 December 2015.

Shilpa Medicare is engaged in the business of bulk drugs manufacturing.

Powered by Capital Market - Live News